Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption

Cancer Letters

Volumn 296, Issue 1, 2010, Pages 106-112

  Liu, Tiancheng ^a   Wu, Lisa Y ^a   Berkman, Clifford E ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Cancer Targeted Technology   (United States)

Author keywords

Apoptosis; Cytoskeleton; Photodynamic therapy; Prostate specific membrane antigen; Pyropheophorbide a

Indexed keywords

ACTIN; ALPHA TUBULIN; BETA TUBULIN; CYTOKERATIN 18; CYTOKERATIN 8; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL DISRUPTION; CELL NUCLEUS; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOSKELETON; HUMAN; HUMAN CELL; INTERMEDIATE FILAMENT; MALE; MICROFILAMENT; MICROTUBULE; MOLECULAR MECHANICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; PROTEIN TRANSPORT;

ACTINS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DEATH; CELL LINE, TUMOR; CYTOSKELETON; HUMANS; INTERMEDIATE FILAMENTS; KERATINS; MALE; MICE; MICROFILAMENTS; MICROTUBULES; PHOTOCHEMOTHERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSLOCATION, GENETIC; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 77954760266     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.04.003     Document Type: Article

References (44)

1. Allison R.R., Downie G.H., Cuenca R., Hu X.H., Childs C.J., Sibata C.H. Photosensitizers in clinical PDT. Photodiagn. Photodynam. Ther. 2004, 1:27-42.
2. Sharman W.M., van Lier J.E., Allen C.M. Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev. 2004, 56:53-76.
3. Detty M.R., Gibson S.L., Wagner S.J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 2004, 47:3897-3915.
4. Berg K., Selbo P.K., Weyergang A., Dietze A., Prasmickaite L., Bonsted A., Engesaeter B.O., Angell-Petersen E., Warloe T., Frandsen N., Hogset A. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J. Microsc. 2005, 218:133-147.
5. Moore C.M., Pendse D., Emberton M. Photodynamic therapy for prostate cancer - a review of current status and future promise. Nat. Clin. Pract. Urol. 2009, 6:18-30.
6. Patel H., Mick R., Finlay J., Zhu T.C., Rickter E., Cengel K.A., Malkowicz S.B., Hahn S.M., Busch T.M. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin. Cancer Res. 2008, 14:4869-4876.
7. Li J., Altschuler M.D., Hahn S.M., Zhu T.C. Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate. Phys. Med. Biol. 2008, 53:4107-4121.
8. Zhu T.C., Finlay J.C., Hahn S.M. Determination of the distribution of light optical properties, drug concentration, and tissue oxygenation in vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J. Photochem. Photobiol. B 2005, 79:231-241.
9. Liu T., Wu L.Y., Kazak M., Berkman C.E. Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 2008, 68:955-964.
10. Liu T., Wu L.Y., Choi J.K., Berkman C.E. In vitro targeted photodynamic therapy with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen. Prostate 2009, 69:585-594.
11. Murphy G.P., Su S., Jarisch J., Kenny G.M. Serum levels of PSMA. Prostate 2000, 42:318-319.
12. Bacich D.J., Pinto J.T., Tong W.P., Heston W.D. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm. Genome: Off. J. Int. Mamm. Genome Soc. 2001, 12(2):117-123.
13. Fair W.R., Israeli R.S., Heston W.D. Prostate-specific membrane antigen. Prostate 1997, 32:140-148.
14. Etienne-Manneville S. Actin and microtubules in cell motility: which one is in control. Traffic 2004, 5:470-477.
15. Mollinedo F., Gajate C. Microtubulesm, microtubule-interfering agents and apoptosis. Apoptosis 2003, 8:413-450.
16. Schutte B., Henfling M., Kolgen W., Bouman M., Meex S., Leers M.P., Nap M., Bjorklund V., Bjorklund P., Bjorklund B., Lane E.B., Omary M.B., Jornvall H., Ramaekers F.C. Keratin 8/18 breakdown and reorganization during apoptosis. Exp. Cell Res. 2004, 297:11-26.
17. Tinnemans M.M., Lenders M.H., ten Velde G.P., Ramaekers F.C., Schutte B. Alterations in cytoskeletal and nuclear matrix-associated proteins during apoptosis. Eur. J. Cell. Biol. 1995, 68:35-46.
18. Ndozangue-Touriguine O., Hamelin J., Breard J. Cytoskeleton and apoptosis. Biochem. Pharmacol. 2008, 76:11-18.
19. Klaiman G., Petzke T.L., Hammond J., Leblanc A.C. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol. Cell Proteom. 2008, 7:1541-1555.
20. Caulin C., Salvesen G.S., Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol. 1997, 138:1379-1394.
21. Gilbert S., Ruel A., Loranger A., Marceau N. Switch in FAS-activated death signaling pathway as result of keratin 8/18-intermediate filament loss. Apoptosis 2008, 13:1479-1493.
22. Mashima T., Naito M., Tsuruo T. Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis. Oncogene 1999, 18:2423-2430.
23. Juarranz A., Espada J., Stockert J.C., Villanueva A., Polo S., Dominguez V., Canete M. Photodamage induced by zinc(II)-phthalocyanine to microtubules, actin, alpha-actinin and keratin of HeLa cells. Photochem. Photobiol. 2001, 73:283-289.
24. Tsai J.C., Wu C.L., Chien H.F., Chen C.T. Reorganization of cytoskeleton induced by 5-aminolevulinic acid-mediated photodynamic therapy and its correlation with mitochondrial dysfunction. Lasers Surg. Med. 2005, 36:398-408.
25. Maftoum-Costa M., Naves K.T., Oliveira A.L., Tedesco A.C., da Silva N.S., Pacheco-Soares C. Mitochondria endoplasmic reticulum and actin filament behavior after PDT with chloroaluminum phthalocyanine liposomal in HeLa cells. Cell Biol. Int. 2008, 32:1024-1028.
26. Uzdensky A., Kolpakova E., Juzeniene A., Juzenas P., Moan J. The effect of sub-lethal ALA-PDT on the cytoskeleton and adhesion of cultured human cancer cells. Biochim. Biophys. Acta 2005, 1722:43-50.
27. Matroule J.Y., Carthy C.M., Granville D.J., Jolois O., Hunt D.W., Piette J. Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 2001, 20:4070-4084.
28. Liu T., Toriyabe Y., Berkman C.E. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody - affinity chromatography. Protein Expres. Purif. 2006, 49:251-255.
29. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57:205-225.
30. Liu T., Toriyabe Y., Kazak M., Berkman C.E. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 2008, 47:12658-12660.
31. Savellano M.D., Pogue B.W., Hoopes P.J., Vitetta E.S., Paulsen K.D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res. 2005, 65:6371-6379.
32. Sun X., Leung W.N. Photodynamic therapy with pyropheophorbide-a methyl ester in human lung carcinoma cancer cell: efficacy, localization and apoptosis. Photochem. Photobiol. 2002, 75:644-651.
33. Caruso J.A., Mathieu P.A., Joiakim A., Leeson B., Kessel D., Sloane B.F., Reiners J.J. Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents. Mol. Pharmacol. 2004, 65:1016-1028.
34. Ouedraogo G., Morliere P., Maziere C., Maziere J.C., Santus R. Alteration of the endocytotic pathway by photosensitization with fluoroquinolones. Photochem. Photobiol. 2000, 72:458-463.
35. White S.R., Williams P., Wojcik K.R., Sun S., Hiemstra P.S., Rabe K.F., Dorscheid D.R. Initiation of apoptosis by actin cytoskeletal derangement in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2001, 24:282-294.
36. Cabado A.G., Leira F., Vieytes M.R., Vieites J.M., Botana L.M. Cytoskeletal disruption is the key factor that triggers apoptosis in okadaic acid-treated neuroblastoma cells. Arch. Toxicol. 2004, 78:74-85.
37. Krajci D., Mares V., Lisa V., Bottone M.G., Pellicciari C. Intranuclear microtubules are hallmarks of an unusual form of cell death in cisplatin-treated C6 glioma cells. Histochem. Cell Biol. 2006, 125:183-191.
38. Mashima T., Naito M., Noguchi K., Miller D.K., Nicholson D.W., Tsuruo T. Actin cleavage by CPP-32/apopain during the development of apoptosis. Oncogene 1997, 14:1007-1012.
39. Oshima R.G. Apoptosis and keratin intermediate filaments. Cell Death Differ. 2002, 9:486-492.
40. Marceau N., Schutte B., Gilbert S., Loranger A., Henfling M.E., Broers J.L., Mathew J., Ramaekers F.C. Dual roles of intermediate filaments in apoptosis. Exp. Cell Res. 2007, 313:2265-2281.
41. Lang S.H., Hyde C., Reid I.N., Hitchcock I.S., Hart C.A., Bryden A.A., Villette J.M., Stower M.J., Maitland N.J. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002, 52:253-263.
42. Moll R., Divo M., Langbein L. The human keratins: biology and pathology. Histochem. Cell Biol. 2008, 129:705-733.
43. Liu T., Wu L.Y., Choi J.K., Berkman C.E. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int. J. Oncol. 2010, 36:777-784.
44. Zhang M., Zhang Z., Blessington D., Li H., Busch T.M., Madrak V., Miles J., Chance B., Glickson J.D., Zheng G. Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters. Bioconjugate Chem. 2003, 14:709-714.